/
Neurology
Alzheimer's Disease
120
Pipeline Programs↗
313
Active Trials↗
151
Companies Involved↗
Alzheimer's Disease is a highly competitive landscape with 120 programs across 151 companies. The most active players are Green Valley (Shanghai) Pharmaceuticals Co., Ltd., Roche, Eli Lilly. 18 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical34
Phase 125
Phase 243
Phase 318
Approved
No programs
Analysis
Modality Breakdown
86%
Small molecule
84 of 98 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 98 classified programs, each share of the total. Modality classified for 87% of 120 pipeline programs.
Analysis
Trial Status
1,063
clinical trials
Completed545 · 51%
Recruiting167 · 16%
Terminated120 · 11%
Not yet recruiting66 · 6%
Unknown status65 · 6%
Active, not recruiting63 · 6%
Other37 · 3%
Clinical Trials
Trial Activity
1063 trials
The Alzheimer's Disease Tau Platform Clinical Trial
Recruiting·—·Phase 2·NCT06957418·900 enrolled
Page 1 of 71
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)